垂体生长激素分泌瘤gsp癌基因的检测及其临床特点的研究

Detection of gsp oncogene in growth hormone secreting pituitary adenomas and clinical characteristics of acromegalic patients with gsp (+) pituitary tumors

目的了解中国肢端肥大症患者垂体生长激素瘤中ｇｓｐ癌基因的发生率及临床特点。方法连续选择４０例确诊为垂体生长激素瘤的患者，从手术获取的垂体瘤组织中提取ＤＮＡ，检测编码Ｇｓα基因２０１位与２２７位氨基酸的核苷酸顺序，以确定ｇｓｐ癌基因的发生率，并总结ｇｓｐ阳性组与阴性组患者的临床特点。结果４０例垂体瘤中有２２例ｇｓｐ阳性的患者，占所研究垂体瘤的５５％。ｇｓｐ阳性组患者的临床特点为ＧＨ分泌更自主、瘤体较小且手术疗效较好。结论结果提示ｇｓｐ突变是垂体生长激素分泌瘤发生的重要的垂体内在因素，ｇｓｐ突变的检测可作为ＧＨ瘤分类及预后的参考指标之一。

Objective To investigate the incidence and clinical characteristics of gsp oncogene of growth hormone secreting pituitary adenomas in Chinese acromegalic patients. Methods 40 acromegalic patients with growth hormone secreting pituitary adenomas were successively studied. Deoxyribonucleic acid (DNA) was extracted from the frozen tumor tissue, and the mutations at codons 201 and 227 were detected. The clinical characteristics of gsp (+) and (-) acromegalic patients were compared. Results Of 40 tumors studied, 22(55%) were gsp positive. The clinical characteristics of gsp (+) acromegalic patients are more autonomous GH secretion, smaller tumor size and higher surgical cure rate. Conclusion The gsp mutation is the major intrinsic defect in the pathogenesis of growth hormone secreting pituitary tumors, and the detection of gsp mutation can be a reference for classification and prognosis of GH tumors.